Bank of America Merrill Lynch is out with its report today on Forest Labs FRX, maintaining Buy.
In a note to clients, Bank of America Merrill Lynch writes, "FRX faces big revenue and EPS cliffs after Lexapro
goes generic in March 2012, but we believe this is
largely factored into valuation. In our view, the stock
could attract more growth interest after the Lexapro
cliff, which will create an EPS trough in F2013, followed by robust EPS growth. We believe base business stability, solid launches of Daliresp and Viibryd, pipeline progress, and smart capital deployment for acquisitions/licensing could help improve sentiment and stock performance."
Bank of America Merrill Lynch maintains a $40 PO on FRX.
Shares of FRX closed Thursday at $39.98, down 0.42% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsBank of America Merrill LynchForest LabsHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in